{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:38:32Z","timestamp":1789267112133,"version":"build-2803163510"},"reference-count":22,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C61296\/A27223"],"award-info":[{"award-number":["C61296\/A27223"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2025,1,18]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>NICE Guideline NG241: identifying and managing familial and genetic risk of ovarian cancer (OC) was published by the National Institute for Health and Care Excellence (NICE) in March 2024. NG241 advises germline genetic testing of genes predisposing to OC in unaffected individuals with an OC family history at different mutation likelihood thresholds depending on age and sex, ranging from 2% to 10% likelihood of finding a germline pathogenic variant (GPV). Prior to implementation of NG241, updates to the NHS England National Genomic Test Directory would be required. Clinical genetics services have to consider equity of access to assessment and testing across all familial cancer types, best use of their limited resources and other factors such as complexity of delivery of clinical pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed data from 8011 patients who provided digital family histories to the South West Thames Centre for Genomics between October 2019 and June 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We estimate 527\/782 (68%) females and 28\/77 (36%) males would meet test criteria for NICE NG241. We estimate we would reject 2919\/5485 (53%) females and 135\/1208 (11%) males with the same likelihood of carrying a GPV, but with a breast cancer rather than OC family history. Testing the familial OC cohort at a universal 5% threshold in OC families would detect ~11 carriers for 229 tests compared with ~8 carriers for 278 tests following NG241 criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data highlight additional factors needing to be considered before the NICE Guideline NG241 can be implemented by regional genetics services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jmg-2024-110481","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:20:27Z","timestamp":1739971227000},"page":"311-316","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of NICE Guideline NG241 \u2018Ovarian Cancer: identifying and managing familial and genetic risk\u2019 on a regional NHS family history and clinical genetics service"],"prefix":"10.1136","volume":"62","author":[{"given":"Alexander","family":"Roe","sequence":"first","affiliation":[{"name":"City St George's, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forman","sequence":"additional","affiliation":[{"name":"Southwest Thames Centre for Genomics, St George's University Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Lalloo","sequence":"additional","affiliation":[{"name":"Clinical Genetics Service, Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri P","family":"McVeigh","sequence":"additional","affiliation":[{"name":"Cancer Genetics, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hanson","sequence":"additional","affiliation":[{"name":"Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1739-7986","authenticated-orcid":false,"given":"Katie","family":"Snape","sequence":"additional","affiliation":[{"name":"City St George's, University of London, London, UK"},{"name":"Southwest Thames Centre for Genomics, St George's University Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2025121605500707000_62.5.311.1","unstructured":"National Institute for Health and Care Excellence . Overview | Ovarian cancer: identifying and managing familial and genetic risk | Guidance. 2024. Available: https:\/\/www.nice.org.uk\/guidance\/ng241"},{"key":"2025121605500707000_62.5.311.2","unstructured":"NICE . Overview | Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | Guidance. 2024. Available: https:\/\/www.nice.org.uk\/guidance\/cg164 [Accessed 01 Jun 2024]."},{"key":"2025121605500707000_62.5.311.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.q807","article-title":"Ovarian cancer: identifying and managing familial and genetic risk-summary of new NICE guidance","volume":"385","author":"Slade","year":"2024","journal-title":"BMJ"},{"key":"2025121605500707000_62.5.311.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-9108-3"},{"key":"2025121605500707000_62.5.311.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.12.1480"},{"key":"2025121605500707000_62.5.311.6","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-4-273"},{"key":"2025121605500707000_62.5.311.7","unstructured":"NHS England . National genomic test directory. 2018. Available: https:\/\/www.england.nhs.uk\/publication\/national-genomic-test-directories\/ [Accessed 01 Jun 2024]."},{"key":"2025121605500707000_62.5.311.8","unstructured":"UK cancer genetics group. 2024. Available: https:\/\/www.ukcgg.org\/ [Accessed 01 Jun 2024]."},{"key":"2025121605500707000_62.5.311.9","unstructured":"CanRisk . 2020. Available: https:\/\/canrisk.org [Accessed 01 Jun 2024]."},{"key":"2025121605500707000_62.5.311.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0406-9"},{"key":"2025121605500707000_62.5.311.11","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-1319"},{"key":"2025121605500707000_62.5.311.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229999","article-title":"Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study","volume":"15","author":"Archer","year":"2020","journal-title":"PLoS One"},{"key":"2025121605500707000_62.5.311.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101230"},{"key":"2025121605500707000_62.5.311.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-024-00407-x"},{"key":"2025121605500707000_62.5.311.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.244"},{"key":"2025121605500707000_62.5.311.16","unstructured":"National disease registration service (NDRS). 2023. Available: https:\/\/digital.nhs.uk\/ndrs\/about\/ncras [Accessed 01 Jun 2024]."},{"key":"2025121605500707000_62.5.311.17","unstructured":"Cancer Research UK . Breast cancer incidence (invasive) statistics. 2024. Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/incidence-invasive#heading-One [Accessed 01 Jun 2024]."},{"key":"2025121605500707000_62.5.311.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02733-4"},{"key":"2025121605500707000_62.5.311.19","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2022-108655"},{"key":"2025121605500707000_62.5.311.20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07549-8"},{"key":"2025121605500707000_62.5.311.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104350"},{"key":"2025121605500707000_62.5.311.22","unstructured":"NHS England . Breast screening: very high risk women surveillance protocols. 2023. Available: https:\/\/www.gov.uk\/government\/publications\/breast-screening-higher-risk-women-surveillance-protocols [Accessed 01 Jun 2024]."}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2024-110481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:50:18Z","timestamp":1765893018000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2024-110481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,4,17]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/jmg-2024-110481"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2024-110481","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}